Answers are grounded in this paper and cite their sources.
Randomized trial evaluates dazukibart’s long-term safety and efficacy in adults with dermatomyositis, indicating positive outcomes.
Objective To evaluate long-term safety and efficacy of dazukibart, a novel anti-interferon beta monoclonal antibody, in adults with moderate-to-severe dermatomyositis (DM). Methods Participants from two cohorts of DM (skin-predominant, SP and muscle-predominant, MP), completing a 24-week phase 2, double-blind study, were enrolled into a 52-week phase 2b, open-label extension (OLE) study, with a 16-week follow-up post treatment (combined study: 92 weeks). Pooled skin-analysis set included all SP and MP DM (with baseline CDASI-A [Cutaneous Dermatomyositis Disease Area and Severity Index-Activity]≥ 14) participants. Primary endpoint was incidence of treatment-emergent adverse events (TEAEs; weeks 24-92). Key secondary endpoints were change in CDASI-A and Total Improvement Score (TIS) (weeks 0-92). Results Participants who received ≥ 1 dose of dazukibart (600 mg) during the OLE study (n = 9 [SP], 15[MP], 16[pooled skin-analysis set]) were analyzed (median age- 49.5 years; 83% females; 96% White). Treatment-related TEAEs were mild (55%), moderate (38%), or severe (7%), with no treatment-related serious adverse events or treatment discontinuations. At week 76, CDASI-A scores improved, with median change from baseline of −24.0 (range −33 to −12; SP), −9.0 (range −32 to 1; MP), and −23.5 (range −33 to −12; pooled skin-analysis set). In the MP cohort, TIS (65.0 [range 2.5 to 9.5]) and associated core set measures (including patient-reported outcomes) improved at week 76. Overall, the observed improvements (slight reduction) in outcomes persisted during the 16-week post-treatment follow-up. Conclusion The safety and efficacy profiles of dazukibart observed at 24 weeks were sustained through 92 weeks.
No takes yet. Share an insight, caveat, or question.
Vleugels et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: